eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | neurofibromatosis 2 |
| Symptom | C0027859|vestibular schwannomas |
| Sentences | 6 |
| PubMedID- 26377980 | Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 22681725 | Additionally, this method of drug delivery may have important implications in the treatment of patients with vestibular schwannomas associated with neurofibromatosis type 2. |
| PubMedID- 24393766 | Two phase ii clinical trials (nct01207687, nct01125046) are assessing the effectiveness of bevacizumab in treating neurofibromatosis 2 patients with symptomatic vestibular schwannomas and recurrent or progressive meningiomas. |
| PubMedID- 20150363 | Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 22483820 | The focus is on management of sporadic, unilateral vestibular schwannomas, because patients with neurofibromatosis type 2 pose different management problems best discussed separately. |
| PubMedID- 24718755 | Audiovestibular characteristics of small cochleovestibular schwannomas in neurofibromatosis type 2. |
Page: 1